AbbVie (ABBV) shares rallied sharply on Monday after the pharmaceutical behemoth announced a definitive agreement to acquire Apogee Therapeutics (APGE) for about $10.9 billion.
The all-cash transaction will see ABBV purchase all outstanding APGE shares for just over $135 each, which translates to a 50% premium on their previous close.